Cerebrolysin 5 ml 5 vials
Sildenafil 100 mg 20 tablets
Prednisolone 5mg 100 tablets
Hypoxen 250 mg 30 capsules
Semax nasal drops 0.1% 3 ml
Tamiflu 75 mg 10 capsules
Ingavirin 90 mg 10 capsues
Ovestin 2 mg 30 tablets
Ovestin Vaginal cream 15g
Macmiror 200 mg 20 tablets
Ventolin nebula 20 ampoules
- Antibacterial medication
- Antifungal medication
- Antiviral Medication
- Cardiovascular medication
- different medication
- Hormonal medication
- Immunosuppressants and immunomodulating medications
- Nervous system
- Pain relievers and anti-inflammatory
- Respiratory system
- Treatment of diseases of the liver and gastrointestinal tract
- Treatment of sensory organs, eyesight and hearing
- Urogenital system
Piracetam 800 mg 30 tablets
De-Nol 120mg 112 tablets
De-Nol 120mg 56 tablets
De-Nol 120mg 32 tablets
finasteride 5mg 30 tablets
Itrazole 100 mg 42 capsules
furasol 15 sachets of 100 mg
Triacort OINTMENT 0.1% 10G
Urseptia 200 mg 20 capsules
Minolexin 50 mg 20 capsules
Immard 200 mg 30 tablets
Adenuric 120 mg 28 tablets
Champix 1 mg 112 tablets
tagista 16 mg 30 tablets
Madopar 125 mg 100 capsules
Cavinton 5 ml 10 vials
Cinnarizine 25 mg 50 tablets
Mydocalm 150 mg 30 tablets
Actovegin 10 ml 5 vials
Betahistine 24 mg 60 tablets
Pronoran 50 mg 30 tablets
Noben 30 mg 30 capsules
Donormil 30 tablets
Vinpocetine 5 mg 50 tablets
Tidomet forte 100 tablets
Persen night 10 capsules
Lamolep 25 mg 30 tablets
Dobrokam 250 mg 30 tablets
Cavinton 5 mg 50 tablets
Baclosan 25 mg 50 tablets
Picamilon 20 mg 30 tablets
Betahistine 16 mg 30 tablets
Memantine 10 mg 30 tablets
Cortexin 10 mg 10 vials
Persen night 20 capsules
Maltofer 100 mg 30 tablets
Manufacturer: TAKEDA Pharmaceuticals
Country of origin: Switzerland
General description: antianemic drug
pharmachologic effect
The preparation of iron. In iron (III), the polymethyltosate hydroxide multinucleated iron (III) hydroxide is surrounded from the outside by a number of covalently bound polymaltosate molecules, which provides a total average molecular weight of about 50 kDa. The structure of the active substance of the preparation of Maltofer® is similar to that of the core of the ferritin protein, the physiological iron depot. Iron (III) hydroxide polymaltose is stable and under physiological conditions does not emit a large number of iron ions. Due to the size, the degree of diffusion of iron (III) polymethyltosate hydroxide through the mucosa is approximately 40 times less than that of the iron-hexahedral complex (II). Iron, which is part of the complex of iron (III) hydroxide polymaltose, is actively absorbed in the intestine.
The effectiveness of the preparation Maltofer® for normalizing the hemoglobin content and iron depot replacement has been demonstrated in numerous randomized controlled clinical trials using a placebo-controlled or active comparator in adults and children with different iron depot status.
Indications
- treatment of iron deficiency without anemia (latent iron deficiency) and treatment of clinically pronounced iron deficiency anemia;
- An increased need for iron during pregnancy, during breastfeeding, blood donation, intensive growth, vegetarianism and the elderly.


.